Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2015, Article ID 746917, 7 pages
http://dx.doi.org/10.1155/2015/746917
Research Article

Adjuvant Iodine131 Lipiodol after Resection of Hepatocellular Carcinoma

1Department of Surgery, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW 2050, Australia
2Department of Nuclear Medicine, Repatriation General Hospital, Hospital Road, Concord, NSW 2137, Australia
3Department of Medical Oncology, Royal North Shore Hospital, Reserve Road, St Leonards, NSW 2065, Australia

Received 18 July 2015; Revised 29 October 2015; Accepted 1 November 2015

Academic Editor: Thomas R. Chauncey

Copyright © 2015 Ruelan V. Furtado et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. F. Altekruse, K. A. McGlynn, and M. E. Reichman, “Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005,” Journal of Clinical Oncology, vol. 27, no. 9, pp. 1485–1491, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. E. Boucher, G. Bouguen, E. Garin, A. Guillygomarch, K. Boudjema, and J.-L. Raoul, “Adjuvant intraarterial injection of 131I-labeled lipiodol after resection of hepatocellular carcinoma: progress report of a case-control study with a 5-year minimal follow-up,” Journal of Nuclear Medicine, vol. 49, no. 3, pp. 362–366, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Breedis and G. Young, “The blood supply of neoplasms in the liver,” The American Journal of Pathology, vol. 30, no. 5, pp. 969–977, 1954. View at Google Scholar · View at Scopus
  4. M. Dhir, E. R. Lyden, L. M. Smith, and C. Are, “Comparison of outcomes of transplantation and resection in patients with early hepatocellular carcinoma: a meta-analysis,” HPB, vol. 14, no. 9, pp. 635–645, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. E. Abdalla and K. Stuart, “Overview of treatment approaches for hepatocellular carcinoma,” in UpToDate, D. Savarese, Ed., UpToDate, Waltham, Mass, USA, 2013. View at Google Scholar
  6. C. H. Park, J. H. Suh, H. S. Yoo, J. T. Lee, and D. I. Kim, “Evaluation of intrahepatic I-131 ethiodol on a patient with hepatocellular carcinoma. Therapeutic feasibility study,” Clinical Nuclear Medicine, vol. 11, no. 7, pp. 514–517, 1986. View at Publisher · View at Google Scholar · View at Scopus
  7. H. S. Yoo, J. T. Lee, K. W. Kim et al., “Nodular hepatocellular carcinoma. Treatment with subsegmental intraarterial injection of iodine 131-labeled iodized oil,” Cancer, vol. 68, no. 9, pp. 1878–1884, 1991. View at Publisher · View at Google Scholar
  8. H. Kobayashi, H. Hidaka, Y. Kajiya et al., “Treatment of hepatocellular carcinoma by transarterial injection of anticancer agents in iodized oil suspension or of radioactive iodized oil solution,” Acta Radiologica: Diagnosis, vol. 27, no. 2, pp. 139–147, 1986. View at Google Scholar · View at Scopus
  9. J.-L. Raoul, D. Guyader, J.-F. Bretagne et al., “Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support,” Journal of Nuclear Medicine, vol. 35, no. 11, pp. 1782–1787, 1994. View at Google Scholar · View at Scopus
  10. R. Furtado, M. Crawford, and C. Sandroussi, “Systematic review and meta-analysis of adjuvant I131 lipiodol after excision of hepatocellular carcinoma,” Annals of Surgical Oncology, vol. 21, no. 8, pp. 2700–2707, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. V. Mazzaferro, G. F. Rondinara, G. Rossi et al., “Milan multicenter experience in liver transplantation for hepatocellular carcinoma,” Transplantation Proceedings, vol. 26, no. 6, pp. 3557–3560, 1994. View at Google Scholar · View at Scopus
  12. F. Y. Yao, L. Ferrell, N. M. Bass, P. Bacchetti, N. L. Ascher, and J. P. Roberts, “Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria,” Liver Transplantation, vol. 8, no. 9, pp. 765–774, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. R. N. H. Pugh, I. M. Murray Lyon, and J. L. Dawson, “Transection of the oesophagus for bleeding oesophageal varices,” The British Journal of Surgery, vol. 60, no. 8, pp. 646–649, 1973. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Bruix, A. Castells, J. Bosch et al., “Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure,” Gastroenterology, vol. 111, no. 4, pp. 1018–1022, 1996. View at Publisher · View at Google Scholar · View at Scopus
  15. E. Boleslawski, G. Petrovai, S. Truant et al., “Hepatic venous pressure gradient in the assessment of portal hypertension before liver resection in patients with cirrhosis,” The British Journal of Surgery, vol. 99, no. 6, pp. 855–863, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Yamamoto, T. Kosuge, T. Takayama et al., “Recurrence of hepatocellular carcinoma after surgery,” The British Journal of Surgery, vol. 83, no. 9, pp. 1219–1222, 1996. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Sumie, R. Kuromatsu, K. Okuda et al., “Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors,” Annals of Surgical Oncology, vol. 15, no. 5, pp. 1375–1382, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. S. B. Edge and C. C. Compton, “The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM,” Annals of Surgical Oncology, vol. 17, no. 6, pp. 1471–1474, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Schemper and T. L. Smith, “A note on quantifying follow-up in studies of failure time,” Controlled Clinical Trials, vol. 17, no. 4, pp. 343–346, 1996. View at Publisher · View at Google Scholar · View at Scopus
  20. W. Y. Lau, T. W. T. Leung, S. K. W. Ho et al., “Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial,” The Lancet, vol. 353, no. 9155, pp. 797–801, 1999. View at Publisher · View at Google Scholar · View at Scopus
  21. W. Y. Lau, E. C. H. Lai, T. W. T. Leung, and S. C. H. Yu, “Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial—update on 5-year and 10-year survival,” Annals of Surgery, vol. 247, no. 1, pp. 43–48, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Y. F. Chung, L. L. P. J. Ooi, D. Machin et al., “Adjuvant hepatic intra-arterial iodine-131-lipiodol following curative resection of hepatocellular carcinoma: a prospective randomized trial,” World Journal of Surgery, vol. 37, no. 6, pp. 1356–1361, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Tabone, L. Vigano, A. Ferrero, R. Pellerito, P. Carbonatto, and L. Capussotti, “Prevention of intrahepatic recurrence by adjuvant 131iodine-labeled lipiodol after resection for hepatocellular carcinoma in HCV-related cirrhosis,” European Journal of Surgical Oncology, vol. 33, no. 1, pp. 61–66, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. T. C. Chua, F. Chu, S. P. Butler et al., “Intra-arterial iodine-131-lipiodol for unresectable hepatocellular carcinoma,” Cancer, vol. 116, no. 17, pp. 4069–4077, 2010. View at Publisher · View at Google Scholar · View at Scopus